Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | CCR9 | P51686 | 1/20 | 0.32 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1352024 | 0.85 | LMNA (0.32) | LMNAKMT2AALDH1A1MAPK1SMN1; SMN2 | |
| SCHEMBL23878604 | 0.84 | LMNA (0.31) | LMNAKMT2ACCR9 | |
| SCHEMBL1350418 | 0.81 | LMNA (0.30) | LMNAKMT2A | |
| SCHEMBL1351517 | 0.81 | CCR9 (0.32) | LMNAKMT2AALDH1A1CCR9 | |
| SCHEMBL3641520 | 0.77 | NAPRT (0.34) | ALDH1A1MAPK1SMN1; SMN2NAPRT | |
| SCHEMBL238763 | 0.75 | SMN1; SMN2 (0.46) | LMNAKMT2AALDH1A1SMN1; SMN2NAPRT | |
| SCHEMBL23878391 | 0.75 | L3MBTL1 (0.35) | LMNAKMT2A | |
| SCHEMBL4440614 | 0.74 | TUBB4A (0.35) | LMNAKMT2AALDH1A1SMN1; SMN2CCR9 | |
| SCHEMBL550049 | 0.73 | CYP3A4 (0.39) | LMNAKMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL1119415 | 0.73 | ALDH1A1 (0.32) | LMNAKMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8461189-B2 | Pyridyl derivatives as histone deacetylase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-06-11 | — | — | US | disclosed |
| US-20100324092-A1 | PYRIDYL AND PYRIMIDINYL DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2010-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324092-A1 | PYRIDYL AND PYRIMIDINYL DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | BRDT, HDAC5, HDAC1 | LMNA 2854/4885KMT2A 111/4885ALDH1A1 966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.